Skip to main content

Advertisement

Table 4 Summary of participants with worsening any time postdose on individual domains of the Neuropsychiatric Inventory

From: Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

Domain 12 mg, n/m (%) 40 mg, n/m (%) Placebo, n/m (%)
Delusions 135/633 (21.3) 124/632 (19.6) 153/639 (23.9)
Hallucinations 84/633 (13.3) 89/632 (14.1) 79/639 (12.4)
Agitation/aggression 245/633 (38.7) 258/632 (40.8) 259/639 (40.5)
Depression/dysphoria 278/633 (43.9) 333/632 (52.7) 256/639 (40.1)
Anxiety 269/633 (42.5) 270/632 (42.7) 250/639 (39.1)
Elation/euphoria 66/633 (10.4) 60/632 (9.5) 62/639 (9.7)
Apathy/indifference 294/633 (46.4) 297/632 (47.0) 306/639 (47.9)
Disinhibition 159/633 (25.1) 155/632 (24.5) 128/639 (20.0)
Irritability/lability 244/633 (38.5) 284/632 (44.9) 244/639 (38.2)
Aberrant motor behavior 177/633 (28.0) 188/632 (29.7) 198/639 (31.0)
Sleep and nighttime behavior disorders 191/633 (30.2) 225/632 (35.6) 182/639 (28.5)
Appetite and eating changes 252/632 (39.9) 255/631 (40.4) 225/639 (35.2)
  1. Worsening was determined by comparing the postdose score to the baseline score
  2. n/m = number of participants with the given item present at that time point/number of participants measured at that time point